An observational study in Chronic Pain Syndrome, sponsored by International Spine, Pain and Performance Center. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by International Spine, Pain and Performance Center · Observational
The purpose of this research is to gather data on the performance and functionality of IV lidocaine infusions prescribed to patients with chronic pain.
3,227 studies on the registry are indexed under Chronic Pain; 729 are open to participants now.
This study's planned enrollment of 100 is below the median of 120 across 753 observational studies indexed under Chronic Pain.
Browse Chronic Pain studies →International Spine, Pain and Performance Center is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult patients with chronic pain who are prescribed to receive an intravenous lidocaine infusion.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Lidocaine IV
Intravenous (IV) infusion of lidocaine. Administered to adult patients with chronic pain.
Change from Baseline in Pain Intensity on the Visual Analog Scale (VAS) at 3 Months
Pain intensity is self-reported by the patient using the VAS to evaluate their level of pain relief. Scores range from 0 to 100, where 0 indicates no pain and 100 indicates the worst possible pain. A negative change score indicates
Time frame: Baseline, 3 months post-infusion
Change from Baseline in Central Sensitization Index (CSI) at 3 Months
Evaluates changes in central sensitization symptoms. The CSI consists of 25 items scored from 0 to 4, with a total score ranging from 0 to 100. Higher scores indicate a higher degree of central sensitization.
Time frame: Baseline, 3 months post-infusion
Patient-Reported Outcomes Measurement Information System (PROMIS)
Evaluates patient-reported health status across multiple domains via the PROMIS-29.
Time frame: Baseline, 1 month post-infusion, 3 months post-infusion, 6 months post-infusion, and 12 months post-infusion
Patient Global Impression of Change (PGIC)
Assesses patient-reported satisfaction and overall impression of change regarding their condition following the infusion.
Time frame: 1 month post-infusion, 3 months post-infusion, 6 months post-infusion, and 12 months post-infusion
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2023 (actual). Primary completion is estimated for Dec 2027, 49 months after the start.
Of 336 non-industry observational studies under Chronic Pain, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 56. This study's planned 49 months is above that.
Counting every sponsor, half of 362 studies reached it within 24 months; a quarter within 12 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
International Spine, Pain and Performance Center